iBio Inc (IBIO)
1.90
-0.07
(-3.55%)
USD |
NYAM |
Jul 05, 15:51
iBio SG&A Expense (Annual): 19.02M for June 30, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
June 30, 2023 | 19.02M |
June 30, 2022 | 21.75M |
June 30, 2021 | 22.03M |
June 30, 2020 | 11.36M |
June 30, 2019 | 12.33M |
June 30, 2018 | 10.68M |
June 30, 2017 | 10.55M |
June 30, 2016 | 7.685M |
June 30, 2015 | 5.022M |
Date | Value |
---|---|
June 30, 2014 | 4.195M |
June 30, 2013 | 4.243M |
June 30, 2012 | 5.623M |
June 30, 2011 | 7.091M |
June 30, 2010 | 2.072M |
June 30, 2009 | 1.805M |
June 30, 2008 | 1.818M |
June 30, 2007 | 1.442M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
11.36M
Minimum
2020
22.03M
Maximum
2021
18.54M
Average
20.38M
Median
SG&A Expense (Annual) Benchmarks
Imunon Inc | 9.743M |
Ocugen Inc | 31.99M |
Avalo Therapeutics Inc | 10.30M |
Petros Pharmaceuticals Inc | 9.262M |
NovaBay Pharmaceuticals Inc | 12.83M |